Literature DB >> 12100861

Incorporation of cyclosporin A in solid lipid nanoparticles (SLN).

Elena Ugazio1, Roberta Cavalli, Maria Rosa Gasco.   

Abstract

The cyclic undecapeptide cyclosporin A (CyA) a potent immunosuppressive drug used in many therapies, is extremely hydrophobic. Commercial products employ solubilising agents to improve gastrointestinal absorption. In the present study CyA solid lipid nanoparticles (SLN) are prepared from warm o/w microemulsion, dispersed in cold water. The matrix chiefly consists of stearic acid, phosphatidylcholine and taurocholate; up to 13% of CyA can be incorporated. The average diameter of CyA-loaded SLNs is below 300 nm and transmission electron microscopy (TEM) analysis shows them to be spherical. In vitro release of CyA from SLNs is low. CyA-loaded SLNs can be proposed for most administration routes, in particular for the duodenal route.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100861     DOI: 10.1016/s0378-5173(02)00268-5

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  12 in total

1.  Physicochemical characteristics, cytotoxicity, and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic acid.

Authors:  Uracha Ruktanonchai; Piyawan Bejrapha; Usawadee Sakulkhu; Praneet Opanasopit; Nuntavan Bunyapraphatsara; Varaporn Junyaprasert; Satit Puttipipatkhachorn
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

2.  Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles.

Authors:  LianDong Hu; Qianbin Xing; Jian Meng; Chuang Shang
Journal:  AAPS PharmSciTech       Date:  2010-03-30       Impact factor: 3.246

3.  Engineering polysaccharide-based polymeric micelles to enhance permeability of cyclosporin A across Caco-2 cells.

Authors:  Mira F Francis; Mariana Cristea; Yali Yang; Françoise M Winnik
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

4.  Modulating Drug Release and Enhancing the Oral Bioavailability of Torcetrapib with Solid Lipid Dispersion Formulations.

Authors:  Yajun Liu; Gino M Salituro; Keun-Joong Lee; Annette Bak; Dennis H Leung
Journal:  AAPS PharmSciTech       Date:  2015-02-18       Impact factor: 3.246

5.  Novel method to label solid lipid nanoparticles with 64cu for positron emission tomography imaging.

Authors:  Erica Andreozzi; Jai Woong Seo; Katherine Ferrara; Angelique Louie
Journal:  Bioconjug Chem       Date:  2011-03-09       Impact factor: 4.774

Review 6.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

7.  Preparation and characterization of cisplatin magnetic solid lipid nanoparticles (MSLNs): effects of loading procedures of Fe3O4 nanoparticles.

Authors:  Sha Zhao; Yongle Zhang; Yazhu Han; Jing Wang; Jie Yang
Journal:  Pharm Res       Date:  2014-08-30       Impact factor: 4.200

8.  Prevention of acute graft-versus-host disease by magnetic nanoparticles of Fe₃O₄ combined with cyclosporin A in murine models.

Authors:  Jian Cheng; Ying Zhou; Baoan Chen; Jun Wang; Guohua Xia; Nan Jin; Jiahua Ding; Chong Gao; Gouming Chen; Yushan Miao; Weilan Li; Ziling Liu; Xuemei Wang
Journal:  Int J Nanomedicine       Date:  2011-10-03

Review 9.  Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles.

Authors:  Susana Martins; Bruno Sarmento; Domingos C Ferreira; Eliana B Souto
Journal:  Int J Nanomedicine       Date:  2007

10.  Viscosified Solid Lipidic Nanoparticles Based on Naringenin and Linolenic Acid for the Release of Cyclosporine A on the Skin.

Authors:  Sonia Trombino; Camilla Servidio; Annarita Stella Laganà; Filomena Conforti; Mariangela Marrelli; Roberta Cassano
Journal:  Molecules       Date:  2020-08-02       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.